No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception

• Published in: Journal of obstetrics and gynaecology Canada Vol. 39; no. 4; pp. 229 - 268.e5
• Main Authors: Black, Amanda, Guilbert, Edith, Costescu, Dustin, Dunn, Sheila, Fisher, William, Kives, Sari, Mirosh, Melissa, Norman, Wendy V., Pymar, Helen, Reid, Robert, Roy, Geneviève, Varto, Hannah, Waddington, Ashley, Wagner, Marie-Soleil, Whelan, Anne Marie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.04.2017
• Subjects: Body Mass Index; Canada; combined hormonal contraception; continuous hormonal contraception; Contraception; Contraceptives, Oral, Combined - administration & dosage; Contraceptives, Oral, Combined - adverse effects; Contraceptives, Oral, Combined - pharmacokinetics; Contraceptives, Oral, Combined - pharmacology; Contraceptives, Oral, Hormonal - administration & dosage; Contraceptives, Oral, Hormonal - adverse effects; Contraceptives, Oral, Hormonal - pharmacokinetics; Contraceptives, Oral, Hormonal - pharmacology; Contraindications, Drug; emergency contraception; family planning; Female; hormonal contraception; Humans; Medication Adherence; Menstruation Disturbances - chemically induced; Myocardial Infarction - chemically induced; Neoplasms - chemically induced; Neoplasms - prevention & control; Obstetrics and Gynecology; oral contraceptive pill; Patient Education as Topic; Pregnancy; Risk Factors; sexual health; Stroke - chemically induced; transdermal contraceptive patch; vaginal contraceptive ring; Venous Thromboembolism - chemically induced; Canada; CDC; DVT; LNG; Cu-IUD; UPA; STI; HFI; E2; transdermal contraceptive patch; UPI; IUC; IUD; MI; EC; SOGC; WHO; AED; EE; sexual health; IUS; Contraception; POP; Canada; emergency contraception; ENG; combined hormonal contraception; RCT; ART; VTE; CYP3A4; FPV; HPV; hormonal contraception; family planning; HDL; vaginal contraceptive ring; COC; oral contraceptive pill; BMI; WY; E2V; continuous hormonal contraception; HIV; PE; C/E; PI; PK; SHBG; CHC; 17 beta-estradiol; progestin-only pill; sexually transmitted infection; high-density lipoprotein; myocardial infarction; Pearl Index (the number of contraceptive failures per 100 women-years of use); cytochrome P450-3A4; World Health Organization; ethinyl estradiol; body mass index; combined oral contraceptive pill; copper intrauterine device; levonorgestrel; fosamprenavir; sex hormone binding globulin; human papillomavirus; human immunodeficiency virus; antiepileptic drug; antiretroviral therapy; hormone-free interval; Centers for Disease Control and Prevention; intrauterine system; unprotected intercourse; intrauterine device; pulmonary embolism; pharmacokinetic; ulipristal acetate; estradiol valerate; etonogestrel; Society of Obstetricians and Gynaecologists of Canada; continuous and/or extended; randomized controlled trial; intrauterine contraceptive; deep vein thrombosis; venous thromboembolism; women-years

To provide guidelines for health care providers on the use of contraceptive methods to prevent pregnancy and on the promotion of healthy sexuality. Overall efficacy of cited contraceptive methods, assessing reduction in pregnancy rate, safety, and side effects; the effect of cited contraceptive meth...